Execution Version	 	Exhibit 10.4




 


NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUBJECT TO SECTION 6 BELOW, AND EXCEPT IN COMPLIANCE
WITH RULE 144 UNDER SAID ACT, NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO
OR AN OPINION OF COUNSEL FOR HOLDER, SATISFACTORY TO COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT OR RECEIPT OF
A NO-ACTION LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION.


 


WARRANT TO PURCHASE SHARES OF COMMON
STOCK


 


March 3, 2017


 


THIS CERTIFIES THAT, for value received,
Cardinal Health 414, LLC, a Delaware limited liability company (“Holder”), is entitled to subscribe for and
purchase TEN MILLION (10,000,000) shares of fully paid and nonassessable shares of Common Stock of NAVIDEA BIOPHARMACEUTICALS,
INC., a Delaware corporation (“Company”), at the Warrant Price (as hereinafter defined), subject to the provisions
and upon the terms and conditions hereinafter set forth. As used herein, the term “Common Stock” shall mean
Company’s presently authorized common stock, $0.001 par value per share, and any stock into which such Common Stock may hereafter
be converted or exchanged and the term “Warrant Shares” shall mean the shares of Common Stock which Holder may
acquire pursuant to this Warrant and any other shares of stock into which such shares of Common Stock may hereafter be converted
or exchanged. This Warrant is being executed and delivered pursuant to the terms of an Asset Purchase Agreement, dated November
23, 2016, between Holder and the Company (the “Purchase Agreement”). Capitalized terms not otherwise defined
herein shall have the respective meanings ascribed to them in the Purchase Agreement.


 


Section 1.           Warrant Price. The
“Warrant Price” shall initially be one and 50/100 dollars ($1.50) per share, subject to adjustment as provided
in Section 7 below.


 


Section 2.           Conditions to Exercise.
The purchase right represented by this Warrant may be exercised at any time, or from time to time, in whole or in part, during
the term commencing on the date hereof and ending at 5:00 p.m. (New York City time) on the fifth anniversary of the date of this
Warrant (the “Expiration Date”).


 


Section 3.           Method of Exercise or Conversion;
Payment; Issuance of Shares; Issuance of New Warrant.


 


(a)       Cash
Exercise. Subject to Section 2 hereof, the purchase right represented by this Warrant may be exercised by Holder, in whole
or in part, by delivery (pursuant to Section 17) to the Company of a duly executed Notice of Exercise in substantially the form
attached hereto, provided that, within three (3) trading days following the date of such exercise, Holder shall surrender
the original of this Warrant and pay to the Company, by certified or bank check, or wire transfer of immediately available funds,
an amount equal to the then applicable Warrant Price per share multiplied by the number of Warrant Shares then being purchased.
In the event of any exercise of the rights represented by this Warrant, certificates for the shares of stock so purchased shall
be in the name of, and delivered to, Holder, or as Holder may direct (subject to the terms of transfer contained herein and upon
payment by such Holder of any applicable transfer taxes). Such delivery shall be made within 10 trading days after exercise of
this Warrant and at the Company’s expense and, unless this Warrant has been fully exercised or expired, a new Warrant having
terms and conditions substantially identical to this Warrant and representing the portion of the Warrant Shares, if any, with respect
to which this Warrant shall not have been exercised, shall also be issued to Holder within 10 days after exercise of this Warrant.
The Warrant Shares shall be deemed to have been issued and Holder or its designee shall be deemed to have become a holder of record
of such Warrant Shares for all purposes as of the date the Notice of Exercise of this Warrant is delivered to the Company.


 






    	 	 	 



     


    

 


(b)       Limited
Conversion Rights. If, at the time of delivery (pursuant to Section 17) to the Company of a duly executed Notice of Exercise
in substantially the form attached hereto, a registration statement (or prospectus) filed by the Company with the U.S. Securities
and Exchange Commission with respect to the resale by Holder of the Warrant Shares (the “Registration Statement”)
is not effective under the Securities Act of 1933, as amended (the “Act”), and the rules and regulations promulgated
thereunder, then in lieu of exercising this Warrant as specified in Section 3(a), Holder may convert this Warrant, in whole or
in part, into Warrant Shares by surrender of the original of this Warrant (together with a duly executed Notice of Exercise in
substantially the form attached hereto) at the principal office of the Company, in which even the Company shall issue to Holder
the number of Warrant Shares computed using the following formula:


 


X = Y(A-B)/A


 


Where:


 


X = the number of Warrant Shares
to be issued to Holder;


 


Y = the number of Warrant Shares requested
to be purchased under this Warrant (at the date of such calculation);


 


A = the Fair Market Value of one share of the Company’s
Common Stock (at the date of such calculation); and


 


B = the Warrant Price (as adjusted to the date of such
calculation).


 


(c)       Fair
Market Value. For purposes of this Section 3, Fair Market Value of one share of the Company’s Common Stock shall mean:


 


(i)       The
last reported sale price quoted on the NYSE MKT or on any other exchange on which the Common Stock is listed, or the average of
the closing bid and asked prices of Common Stock quoted in the Over-The-Counter Market Summary, whichever is applicable, as published
in the Eastern Edition of the Wall Street Journal for the three (3) trading days prior to the date of determination of the Fair
Market Value; or


 






    	 	2	 



     


    

 


(ii)       In
the event of an exercise in connection with a merger, acquisition or other consolidation in which the Company is not the surviving
entity, the value to be received per share of Common Stock by all holders of the Common Stock in such transaction as determined
in the reasonable good faith judgment of the Company’s Board of Directors; or


 


(iii)       In
any other instance, the value as determined in the reasonable good faith judgment of the Company’s Board of Directors.


 


In the event of Section 3(c)(ii) or 3(c)(iii) above, the Company’s
Board of Directors shall prepare a certificate, to be signed by an authorized officer of the Company, setting forth in reasonable
detail the basis for and method of determination of the per share Fair Market Value of the Common Stock. The Board of Directors
will also certify to Holder that this per share Fair Market Value will be applicable to all holders of Company’s Common Stock.
Such certifications must be made to Holder, in the event of Section 3(c)(ii) above, at least ten (10) business days prior to the
proposed effective date of the merger, acquisition or other consolidation, and in the event of Section 3(c)(iii), promptly after
exercise of this Warrant.


 


(d)       Automatic
Exercise. To the extent this Warrant is not previously exercised, it shall be deemed to have been automatically converted in
accordance with Sections 3(b) and 3(c) hereof (even if not surrendered) as of immediately before its expiration, involuntary termination
or cancellation if the Registration Statement is not effective as of such time (including, without limitation, pursuant to Section
3(e)(ii)) if the then-Fair Market Value of a Warrant Share exceeds the then-Warrant Price, unless Holder notifies the Company in
writing to the contrary prior to such automatic exercise.


 


(e)       Treatment
of Warrant Upon Acquisition of the Company.


 


(i)       Certain
Definitions; Acquisitions. For the purpose of this Warrant: “Acquisition” means, whether direct or indirect
and whether in one or a series of related transactions, any sale, license, assignment, or other disposition of all or substantially
all of the assets of the Company, or any reorganization, consolidation, or merger of the Company, or sale of outstanding Company
securities by holders thereof, where the holders of the Company’s securities as of immediately before the transaction beneficially
own less than a majority of the outstanding voting securities of the successor or surviving entity as of immediately after the
transaction (or, if the successor or surviving entity is a wholly-owned subsidiary of another corporation, such successor or surviving
entity’s parent). For purposes of this Section 3(e), “Affiliate” shall mean any person or entity that
owns or controls directly or indirectly ten percent (10%) or more of the voting capital stock of the Company, any person or entity
that controls or is controlled by or is under common control with such persons or entities, and each of such person’s or
entity’s officers, directors, joint venturers or partners, as applicable. The Company shall provide Holder with written notice
of any proposed Acquisition not later than ten (10) Business Days prior to the closing thereof setting forth the material terms
and conditions thereof, and shall provide Holder with copies of the draft transaction agreements and other documents in connection
therewith and with such other information respecting such proposed Acquisition as may reasonably be requested by Holder. If the
Acquisition described in such notice is terminated or abandoned prior to the consummation thereof, the Company shall provide prompt
notice thereof to Holder and, unless Holder advises the Company in a written notice that it elects to reaffirm the exercise, any
purported exercise of this Warrant in connection with such proposed Acquisition shall be null and void. For the avoidance of doubt,
the transactions contemplated by the Purchase Agreement do not constitute an Acquisition for purposes of this Warrant.


 






    	 	3	 



     


    

 


(ii)       Acquisition
for Cash. Holder agrees that, in the event of an Acquisition in which the sole consideration is cash, and such consideration
is to be received by the holders of the Company’s Common Stock in respect of their shares of the Common Stock at the closing
of the Acquisition, this Warrant shall be automatically exercised (or terminated) as provided in Section 3(d) (even if a Registration
Statement has been declared and remains effective by the SEC) on and as of the closing of such Acquisition to the extent not previously
exercised.


 


(iii)       Asset
Sale. In the event of an Acquisition that is an arm’s length sale of all or substantially all of the Company’s
assets (and only its assets) to a third party that is not an Affiliate of the Company (a “True Asset Sale”),
Holder may either (A) exercise its conversion or purchase right under this Warrant pursuant to Sections 3(a) or 3(b) (even if a
Registration Statement has been declared and remains effective by the SEC), respectively, and such exercise will be deemed effective
immediately prior to the consummation of such Acquisition, or (B) permit the Warrant to continue until the Expiration Date if the
Company continues as a going concern following the closing of any such True Asset Sale. For the avoidance of doubt, the transactions
contemplated by the Purchase Agreement do not constitute a True Asset Sale for purposes of this Warrant.


 


(iv)       Assumption
of Warrant. Upon the closing of any Acquisition other than as particularly described in Section 3(e)(ii) or 3(e)(iii) above
(and, for the avoidance of doubt, including any such Acquisition in which the Company is not the surviving entity), the Company
shall, unless Holder requests otherwise, cause the surviving or successor entity to assume this Warrant and the obligations of
the Company hereunder, and this Warrant shall, from and after such closing, be exercisable for the same class, number and kind
of securities, cash and other property as would have been paid for or in respect of the shares issuable (as of immediately prior
to such closing) upon exercise in full hereof as if such shares had been issued and outstanding on and as of such closing, at an
aggregate Warrant Price equal to the aggregate Warrant Price in effect as of immediately prior to such closing (and subject to
further adjustment thereafter from time to time in accordance with the provisions of this Warrant).


 


(v)       Conditional
Exercise. Notwithstanding any other provision hereof, if an exercise of this Warrant is to be made in connection with an Acquisition,
such exercise may at the election of Holder be conditioned upon the consummation of such Acquisition, in which case such exercise
shall not be deemed to be effective until immediately prior to the consummation of the Acquisition.


 


Section 4.           Representations and Warranties
of Holder and the Company.


 


(a)       Representations
and Warranties of Holder. Holder represents and warrants to the Company as of the date hereof with respect to this Warrant
as follows:


 






    	 	4	 



     


    

 


(i)       Evaluation.
Holder has substantial experience in evaluating and investing in private placement transactions of securities of companies similar
to the Company so that Holder is capable of evaluating the merits and risks of its investment in the Company and has the capacity
to protect its interests.


 


(ii)       Resale.
Except for transfers to an affiliate of Holder, Holder is acquiring this Warrant and the Warrant Shares issuable upon exercise
of this Warrant (collectively, the “Securities”) for investment for its own account and not with a view to,
or for resale in connection with, any distribution thereof. Holder understands that the Securities have not been registered under
the Act by reason of a specific exemption from the registration provisions of the Act which depends upon, among other things, the
bona fide nature of the investment intent as expressed herein.


 


(iii)       Rule
144. Holder acknowledges that the Securities must be held indefinitely unless subsequently registered under the Act or an exemption
from such registration is available. Holder is aware of the provisions of Rule 144 promulgated under the Act.


 


(iv)       Accredited
Investor. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act.


 


(b)       Representations
and Warranties by the Company. The Company hereby represents and warrants to Holder that the statements in the following paragraphs
of this Section 4(b) are true and correct as of the date hereof.


 


(i)       Corporate
Organization and Authority. The Company (A) is a corporation duly organized, validly existing and in good standing under the
laws of the jurisdiction of its organization, (B) has the corporate power and authority to own and operate its properties and to
carry on its business as now conducted and as proposed to be conducted, and (C) is qualified as a foreign corporation in all jurisdictions
where such qualification is required.


 


(ii)       Corporate
Power. The Company has all requisite legal and corporate power and authority to execute, issue and deliver this Warrant, to
issue the Warrant Shares issuable upon exercise or conversion of this Warrant, and to carry out and perform its obligations under
this Warrant and any related agreements.


 


(iii)       Authorization;
Enforceability. All corporate action on the part of the Company, its officers, directors and shareholders necessary for the
authorization, execution, delivery and performance of its obligations under this Warrant and for the authorization, issuance and
delivery of this Warrant and the Warrant Shares issuable upon exercise of this Warrant has been taken and this Warrant constitutes
the legally binding and valid obligation of the Company enforceable in accordance with its terms.


 


(iv)       Valid
Issuance of Warrant and Warrant Shares. This Warrant has been validly issued and is free of restrictions on transfer other
than restrictions on transfer set forth herein and under applicable state and federal securities laws. The Warrant Shares issuable
upon exercise or conversion of this Warrant, when issued, sold and delivered in accordance with the terms of this Warrant for the
consideration expressed herein, will be duly and validly issued, fully paid and nonassessable, and will be free of restrictions
on transfer other than restrictions under this Warrant and under applicable state and federal securities laws. Subject to applicable
restrictions on transfer, the issuance and delivery of this Warrant and the Warrant Shares issuable upon exercise or conversion
of this Warrant are not subject to any preemptive or other similar rights or any liens or encumbrances except as specifically set
forth in the Company’s Amended and Restated Certificate of Incorporation (“Certificate of Incorporation”)
or this Warrant. Unless a Registration Statement has been declared and remains effective by the SEC at the time of the issuance
of the Warrant Shares, the offer, sale and issuance of the Warrant Shares, as contemplated by this Warrant, are exempt from the
prospectus and registration requirements of applicable United States federal and state security laws, and neither the Company nor
any authorized agent acting on its behalf has taken or will take any action hereafter that would cause the loss of such exemption,
except with respect to filing, causing to become effective, and maintaining the effectiveness of, the Registration Statement.


 






    	 	5	 



     


    

 


(v)       No
Conflict. The execution, delivery and performance of this Warrant will not (A) contravene any of the organizational documents
of the Company, (B) violate any material Legal Requirement, (C) require any action by, filing, registration, qualification with,
or approval, consent or withholding of objections from, any Governmental Authority or any other Person, except those which have
been obtained and are in full force and effect, (D) result in the creation of any Lien on any of the Company’s Real Property,
or (E) result in any breach of or constitute a default under, or permit the termination or acceleration of, any Material Contract
to which the Company is a party.


 


Section 5.           Legends.


 


(a)       Legend.
Each certificate representing the Warrant Shares shall, unless at the time of issuance the Registration Statement has been declared
and remains effective by the SEC, be endorsed with substantially the following legend:


 


THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 AND MAY NOT BE TRANSFERRED (UNLESS SUCH TRANSFER IS TO AN AFFILIATE OF HOLDER) UNLESS COVERED BY AN EFFECTIVE
REGISTRATION STATEMENT UNDER SAID ACT, A “NO ACTION” LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION WITH RESPECT
TO SUCH TRANSFER, A TRANSFER MEETING THE REQUIREMENTS OF RULE 144 OF THE SECURITIES ACT OF 1933, OR (IF REASONABLY REQUIRED BY
THE COMPANY) AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY SUCH TRANSFER IS EXEMPT FROM SUCH REGISTRATION.


 


The Company need not enter into its stock records a transfer
of Warrant Shares unless the conditions specified in the foregoing legend are satisfied or the Registration Statement was declared
and remained effective by the SEC at the time of issuance of the Warrant Shares. The Company may also instruct its transfer agent
not to allow the transfer of any of the Warrant Shares unless the conditions specified in the foregoing legend are satisfied or
the Registration Statement was declared and remained effective by the SEC at the time of issuance of the Warrant Shares.


 






    	 	6	 



     


    

 


(b)       Removal
of Legend and Transfer Restrictions. The legend relating to the Act endorsed on a certificate pursuant to paragraph 5(a) of
this Warrant shall not be affixed or shall be removed and the Company shall issue a certificate without such legend to Holder if
(i) the Securities are registered under the Act and a prospectus meeting the requirements of Section 10 of the Act is available,
or (ii) Holder provides to the Company an opinion of counsel for Holder reasonably satisfactory to the Company, or other evidence
reasonably satisfactory to the Company, to the effect that public sale, transfer or assignment of the Securities may be made without
registration and without compliance with any restriction such as Rule 144.


 


Section 6.           Transfers of Warrant.
In connection with any transfer by Holder of this Warrant, the Company may require the transferee to provide the Company with written
representations and warranties that transferee is acquiring this Warrant and the Warrant Shares to be issued upon exercise for
investment purposes only and not with a view to any sale or distribution, and may require a legal opinion, in form and substance
satisfactory to the Company and its counsel, stating that such transfer is exempt from the registration and prospectus delivery
requirements of the Act; provided that the Company shall not require an opinion of counsel if the transfer is to an affiliate
of Holder or the Registration Statement has been declared and remains effective by the SEC at the time of such transfer. Following
any transfer of this Warrant, at the request of either the Company or the transferee, the transferee shall surrender this Warrant
to the Company in exchange for a new warrant of like tenor and date, executed by the Company. Upon any partial transfer, the Company
will also execute and deliver to Holder a new warrant of like tenor with respect to the portion of this Warrant not so transferred.
Subject to the foregoing, this Warrant is transferable on the books of the Company at its principal office by the registered Holder
upon surrender of this Warrant properly endorsed.


 


Section 7.           Adjustment for Certain
Events. The number and kind of securities purchasable upon the exercise of this Warrant and the Warrant Price shall be subject
to adjustment from time to time upon the occurrence of certain events, as follows:


 


(a)       Reclassification
or Merger. In case of (i) any reclassification or change of securities of the class issuable upon exercise of this Warrant
(other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of a subdivision
or combination), (ii) any merger of the Company with or into another corporation (other than a merger with another corporation
in which the Company is the acquiring and the surviving corporation and which does not result in any reclassification or change
of outstanding securities issuable upon exercise of this Warrant), or (iii) any sale of all or substantially all of the assets
of the Company, the Company, or such successor or purchasing corporation, as the case may be, shall duly execute and deliver to
Holder a new Warrant (in form and substance satisfactory to Holder of this Warrant), or the Company shall make appropriate provision
without the issuance of a new Warrant, so that Holder shall have the right to receive, at a total purchase price not to exceed
that payable upon the exercise of the unexercised portion of this Warrant, and in lieu of the Warrant Shares theretofore issuable
upon exercise or conversion of this Warrant, the kind and amount of shares of stock, other securities, money and property receivable
upon such reclassification, change, merger or sale by a holder of the number of shares of Common Stock then purchasable under this
Warrant, or in the case or such a merger or sale in which the consideration paid consists all or in part of assets other than securities
of the successor or purchasing corporation, at the option of Holder, the securities of the successor or purchasing corporation
having a value at the time of the transaction equivalent to the value of the Warrant Shares purchasable upon exercise of this Warrant
at the time of the transaction. Any new Warrant shall provide for adjustments that shall be as nearly as equivalent as may be practicable
to the adjustments provided for in this Section 7. The provisions of this subparagraph (a) shall similarly apply to successive
reclassifications, changes, mergers and transfers.


 






    	 	7	 



     


    

 


(b)       Subdivision
or Combination of Shares. If the Company at any time while this Warrant remains outstanding and unexpired shall subdivide or
combine its outstanding shares of Common Stock, the Warrant Price shall be proportionately decreased and the number of Warrant
Shares issuable hereunder shall be proportionately increased in the case of a subdivision and the Warrant Price shall be proportionately
increased and the number of Warrant Shares issuable hereunder shall be proportionately decreased in the case of a combination.


 


(c)       Stock
Dividends and Other Distributions. If the Company at any time while this Warrant is outstanding and unexpired shall (i) pay
a dividend with respect to Common Stock payable in Common Stock, then the Warrant Price shall be adjusted, from and after the date
of determination of shareholders entitled to receive such dividend or distribution, to that price determined by multiplying the
Warrant Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall be the total
number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which
shall be the total number of shares of Common Stock outstanding immediately after such dividend or distribution; or (ii) make any
other distribution with respect to Common Stock (except any distribution specifically provided for in Sections 7(a) and 7(b)),
including in connection with any direct or indirect sale, license, assignment or other disposition of any of the material assets
(whether in one or a series of related transactions and regardless of the form of transaction) associated with the “Manocept”
or “Macrophage Therapeutics” subsidiaries or divisions of the Company, or any sale or other disposition of the securities
of any such subsidiary, then, in each such case, provision shall be made by the Company such that Holder shall receive upon exercise
of this Warrant a proportionate share of any such dividend or distribution as though it were Holder of the Warrant Shares as of
the record date fixed for the determination of the shareholders of the Company entitled to receive such dividend or distribution.


 


(d)       Adjustment
of Number of Shares. Upon each adjustment in the Warrant Price, the number of Warrant Shares purchasable hereunder shall be
adjusted, to the nearest whole share, to the product obtained by multiplying the number of Warrant Shares purchasable immediately
prior to such adjustment in the Warrant Price by a fraction, the numerator of which shall be the Warrant Price immediately prior
to such adjustment and the denominator of which shall be the Warrant Price immediately thereafter.


 


Section 8.           Notice of Adjustments;
Redemption. Whenever any Warrant Price or the kind or number of securities issuable under this Warrant shall be adjusted pursuant
to Section 7 hereof, the Company shall prepare a certificate signed by an officer of the Company setting forth, in reasonable detail,
the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the Warrant
Price and number or kind of shares issuable upon exercise of this Warrant after giving effect to such adjustment, and within thirty
(30) days of such adjustment shall cause copies of such certificates to be delivered to Holder in accordance with Section 17 hereof.


 






    	 	8	 



     


    

 


Section 9.           Exchange Act Reports.
With a view to making available to Holder the benefits of Rule 144, the Company shall, so long as it is subject to the reporting
requirements of the Act and the Exchange Act (collectively, the “Acts”), but not during any period in which
the Registration Statement is effective with the SEC, (i) at all times make and keep available adequate current public information,
as those terms are understood and defined in Rule 144, (ii) use commercially reasonable efforts to file with the SEC in a timely
manner all reports and other documents required of the Company under the Acts, and (iii) furnish Holder upon written request a
written statement by the Company that it has complied with the reporting requirements of Rule 144 and the Acts, or that it qualifies
as a registrant whose securities may be resold pursuant to Form S-3, and such other information as may be reasonably requested
in availing Holder of any rule or regulation of the SEC that permits the sale of any securities without registration or pursuant
to Form S-3.


 


Section 10.           No Fractional Shares.
No fractional shares of Common Stock will be issued in connection with any exercise or conversion hereunder, but in lieu of such
fractional share the Company shall make a cash payment therefor upon the basis of the Warrant Price then in effect.


 


Section 11.           Charges, Taxes and Expenses.
Issuance of certificates for shares of Common Stock upon the exercise or conversion of this Warrant shall be made without charge
to Holder for any United States or state of the United States documentary stamp tax or other incidental expense with respect to
the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be
issued in the name of Holder.


 


Section 12.           No Shareholder Rights
Until Exercise. Except as expressly provided herein, this Warrant does not entitle Holder to any voting rights or other rights
as a shareholder of the Company prior to the exercise hereof.


 


Section 13.           Registry of Warrant.
The Company shall maintain a registry showing the name and address of the registered Holder of this Warrant. This Warrant may be
surrendered for exchange or exercise, in accordance with its terms, at such office or agency of the Company, and the Company and
Holder shall be entitled to rely in all respects, prior to written notice to the contrary, upon such registry.


 


Section 14.           Loss, Theft, Destruction
or Mutilation of Warrant. Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction
or mutilation of this Warrant, and, in the case of loss, theft, or destruction, of indemnity reasonably satisfactory to it, and,
if mutilated, upon surrender and cancellation of this Warrant, the Company will execute and deliver a new Warrant, having terms
and conditions substantially identical to this Warrant, in lieu hereof.


 






    	 	9	 



     


    

 


Section 15.           Miscellaneous.


 


(a)       Issue
Date. The provisions of this Warrant shall be construed and shall be given effect in all respect as if it had been issued and
delivered by the Company on the date hereof.


 


(b)       Successors.
This Warrant shall be binding upon any successors or assigns of the Company.


 


(c)       Headings.
The headings used in this Warrant are used for convenience only and are not to be considered in construing or interpreting this
Warrant.


 


(d)       Saturdays,
Sundays, Holidays. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall be a Saturday or a Sunday or shall be a legal holiday in the State of Delaware, then such action may be taken or such
right may be exercised on the next succeeding day not a Saturday, Sunday or a legal holiday.


 


Section 16.           No Impairment. The
Company will not, by amendment of its Certificate of Incorporation or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such
terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of Holder against
impairment.


 


Section 17.           Addresses. All notices
or other communications given in connection with this Warrant shall be in writing, shall be addressed to the parties at their respective
addresses set forth below (unless and until a different address may be specified in a written notice to the other party delivered
in accordance with this Section 17), and shall be deemed given (a) on the date of receipt if delivered by hand, (b) on the next
business day after being sent by a nationally-recognized overnight courier, or (c) on the third business day after being sent by
registered or certified mail, return receipt requested and postage prepaid.


 


If to Company:






Navidea Biopharmaceuticals, Inc.


5600 Blazer Parkway, Suite 200


Dublin, OH 43017

Attention: Dr. Michael Goldberg, Chief Executive Officer


Email: mgoldberg@navidea.com


 


Navidea Biopharmaceuticals, Inc.


5600 Blazer Parkway, Suite 200


Dublin, OH 43017

Attention: Jed Latkin, Chief Financial Officer


Email: jlatkin@navidea.com


 




    	 	10	 



     


    

 


 


If to Holder:


 


c/o Cardinal Health, Inc.

7000 Cardinal Place

Dublin, OH 43017

Attention: Vice President, Associate General Counsel, Mergers & Acquisitions

Attention: Senior Vice President, Deputy General Counsel, Corporate: Legal and Compliance


Facsimile: (614) 757-6448


 


with a copy to (which will not constitute notice):


 


Jones Day

P.O. Box 165017

Columbus, Ohio 43216-5017

Attention: Jeffrey D. Litle

Facsimile: (614) 461-4198

Email: jdlitle@jonesday.com


 


Section 18.           WAIVER OF JURY TRIAL.
EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY
JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS WARRANT OR THE WARRANT
SHARES.


 


Section 19.           GOVERNING LAW. THIS
WARRANT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE (WITHOUT REGARD TO THE CONFLICT
OF LAW PRINCIPLES OF SUCH STATE) EXCEPT THAT THE GENERAL CORPORATION LAW OF DELAWARE SHALL APPLY TO MATTERS SPECIFICALLY ADDRESSED
THEREIN.


 


Section 20.           Covenants Related to Registration
Statement.


 


(a)       Filings.
The Company shall, as far in advance as practicable and in any event at least ten (10) Business Days, prior to filing a Registration
Statement or prospectus, or any amendment or supplement thereto, furnish to Holder for review a copy of the Registration Statement
proposed to be filed, each amendment and supplement to such Registration Statement (in each case including all exhibits thereto
and documents incorporated by reference therein), the prospectus included in such Registration Statement (including each preliminary
prospectus), and such other documents as Holder may request in order to facilitate the disposition of the Warrant Shares, and the
Company shall incorporate any reasonable changes therein requested by Holder prior to filing. After the filing of a Registration
Statement, the Company shall promptly, and in no event more than two (2) Business Days after such filing, notify Holder of
such filing, and shall further notify Holder promptly, and in no event more than two (2) Business Days of the occurrence of
any of the following: (i) when such Registration Statement becomes effective; (ii) when any post-effective amendment
to such Registration Statement becomes effective; (iii) the issuance or threatened issuance by the SEC of any stop order;
and (iv) any request by the SEC for any amendment or supplement to such Registration Statement or any prospectus relating
thereto.


 






    	 	11	 



     


    

 


(b)       Information.
Holder shall provide such information as may reasonably be requested by the Company in connection with the preparation of any Registration
Statement, including amendments and supplements thereto, in order to effect the registration of the resale of the Warrant Shares
under the Act and in connection with the Company’s obligation to comply with federal and applicable state securities laws.


 


(c)       Indemnity.
The Company agrees to indemnify and hold harmless Holder and its respective officers, employees, Affiliates, directors, partners,
members, attorneys and agents, and each Person, if any, who controls Holder (within the meaning of Section 15 of the Act or
Section 20 of the Exchange Act) (each, an “Indemnified Party”), from and against any Loss arising out of
or based upon any untrue statement (or allegedly untrue statement) of a material fact contained in any Registration Statement,
any prospectus, or any amendment or supplement to such Registration Statement, or arising out of or based upon any omission (or
alleged omission) to state a material fact required to be stated therein or necessary to make the statements therein not misleading;
provided that the Company will not be liable in any such case to the extent that any such Loss arises out of or is based
upon any untrue statement or allegedly untrue statement or omission or alleged omission made in such Registration Statement, prospectus,
or any such amendment or supplement, in reliance upon and in conformity with information furnished to the Company by Holder specifically
for inclusion in such Registration Statement, prospectus, or any such amendment or supplement.


 


(d)       No
Obligation to Register Warrant Shares. Nothing herein shall be deemed to require the Company to file, cause to become effective
or continue to maintain the effectiveness of, any Registration Statement, and any such actions taken by the Company shall be taken
in the sole and absolute discretion of the Company.


 


[Remainder of Page Intentionally Left
Blank]


 




    	 	12	 



     


    

 


IN WITNESS WHEREOF, the Company has caused
this Warrant to be executed by its officer thereunto duly authorized.


 


NAVIDEA BIOPHARMACEUTICALS, INC.






 


By: /s/ Jed Latkin                                     

Name: Jed Latkin                                       

Title: Interim Chief Financial Officer/Chief Operating Officer


  


CARDINAL HEALTH 414, LLC






 


By: /s/ Tiffany Olson                               

Name: Tiffany Olson                               

Title: President- Nuclear Pharmacy Services


 




    	 	 	 



     


    

 


NOTICE OF EXERCISE


 


To:


 


[_____________]

[_____________]

[_____________]

Attn: [___________]


 


		1.	The undersigned Warrantholder (“Holder”) elects to acquire shares of the Common Stock (the “Common
Stock”) of NAVIDEA BIOPHARMACEUTICALS, INC. (the “Company”), pursuant to the terms of the Warrant
to Purchase Common Stock dated [____], 2016 (the “Warrant”).



 


		2.	Holder exercises its rights under the Warrant as set forth below:



 





	 	(    )	Holder elects to purchase ______________ shares of Common Stock as provided in Section 3(a) and tenders herewith a check in the amount of $__________ as payment of the purchase price.
	 	 	 
	 	(    )	If permitted by Section 3(b) of the Warrant, Holder elects to convert the purchase rights into shares of Common Stock as provided in Section 3(b) of the Warrant.




 


		3.	Holder surrenders the Warrant with this Notice of Exercise.



 


Holder represents that it is acquiring the aforesaid
shares of Common Stock for investment and not with a view to or for resale in connection with distribution, and it has no present
intention of distributing or reselling the shares.


 


Please issue a certificate representing the shares
of the Common Stock in the name of Holder or in such other name as is specified below:


 


Name:   ___________________________________

Address:   _________________________________

Taxpayer ID:   ______________________________


 


[HOLDER]


 


By: ________________________

Name: ______________________

Title: _______________________

Date: _______________________